Physician profile
Allison Collings
NPI 1194165423
$1,109.33
in general payments reported to CMS, 2019-2025
18 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $319 · 2024: $550 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $176.65 | 2023-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $153.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $135.09 | 2023-2025 | |
| Abbvie INC. | $130.15 | 2023-2024 | |
| Astellas Pharma US INC | $95.66 | 2023-2025 | Veozah |
| Lilly USA, LLC | $59.81 | 2023-2024 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $48.44 | 2023-2024 | |
| Exact Sciences Corporation | $47.92 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $47.73 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $42.04 | 2024-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $34.62 | 2024 | Farxiga |
| Axsome Therapeutics, INC. | $30.63 | 2023 | Auvelity |
| Tolmar, INC. | $30.57 | 2023-2024 | |
| Halozyme INC | $16.57 | 2023 | |
| Merck Sharp & Dohme LLC | $16.20 | 2024 | Capvaxive |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.29 | 2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $14.38 | 2025 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Collings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.